My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Onconetix, Inc. - Common Stock (NQ:ONCO)

3.120 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Onconetix, Inc. - Common Stock

Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
From Onconetix, Inc.
Via GlobeNewswire
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
From Onconetix, Inc.
Via GlobeNewswire
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
From Onconetix, Inc.
Via GlobeNewswire
ONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement
From Onconetix, Inc.
Via GlobeNewswire
Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel
From Onconetix, Inc.
Via GlobeNewswire
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
From Onconetix, Inc.
Via GlobeNewswire
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
From Onconetix, Inc.
Via GlobeNewswire
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
From Onconetix, Inc.
Via GlobeNewswire
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
From Onconetix, Inc.
Via GlobeNewswire
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
From Onconetix, Inc.
Via GlobeNewswire
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
From Onconetix, Inc.
Via GlobeNewswire
Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
From Onconetix, Inc.
Via GlobeNewswire
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
From Onconetix, Inc.
Via GlobeNewswire
Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
From Onconetix, Inc.
Via GlobeNewswire
Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
From Onconetix, Inc.
Via GlobeNewswire
Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds
From Onconetix, Inc.
Via GlobeNewswire
Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds
From Onconetix, Inc.
Via GlobeNewswire
Nasdaq Stocks Under $1 to Watch Now! VTAK, IVP, ONCO, AKTS, RDHL
Via AB Newswire
Topics Supply Chain
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.